LaurifolineCAS# 7224-61-5 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 7224-61-5 | SDF | Download SDF |
| PubChem ID | 12305611 | Appearance | Brown oil |
| Formula | C20H24NO4 | M.Wt | 342.4 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Synonyms | (+)-Laurifoline | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (6aS)-2,10-dimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-1,9-diol | ||
| SMILES | C[N+]1(CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)O)O)OC)C | ||
| Standard InChIKey | ZDVDVLRYVOZWMP-AWEZNQCLSA-O | ||
| Standard InChI | InChI=1S/C20H23NO4/c1-21(2)6-5-11-9-17(25-4)20(23)19-13-10-16(24-3)15(22)8-12(13)7-14(21)18(11)19/h8-10,14H,5-7H2,1-4H3,(H-,22,23)/p+1/t14-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Laurifoline is a potential NF-κB inhibitor and a potential β2 -adrenegic receptor agonist, it can not only inhibit Pseudomonas aeruginosa PAK strain-induced inflammatory responses via a negative regulation of the Braf protein that participates in MAPK signaling pathway but also activate the β2 -adrenegic receptor. 2. Laurifoline may show anti-HBV activities in vitro using the HBV transfected Hep G2.2.15 cell line. |
| Targets | NF-kB | Adrenergic Receptor | MAPK | HBV |
Laurifoline Dilution Calculator
Laurifoline Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9206 mL | 14.6028 mL | 29.2056 mL | 58.4112 mL | 73.014 mL |
| 5 mM | 0.5841 mL | 2.9206 mL | 5.8411 mL | 11.6822 mL | 14.6028 mL |
| 10 mM | 0.2921 mL | 1.4603 mL | 2.9206 mL | 5.8411 mL | 7.3014 mL |
| 50 mM | 0.0584 mL | 0.2921 mL | 0.5841 mL | 1.1682 mL | 1.4603 mL |
| 100 mM | 0.0292 mL | 0.146 mL | 0.2921 mL | 0.5841 mL | 0.7301 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2alpha-Hydroxyeupatolide 8-O-angelate
Catalog No.:BCN7340
CAS No.:72229-39-1
- 2-Hydroxyeupatolide
Catalog No.:BCN2490
CAS No.:72229-33-5
- Echitovenidine
Catalog No.:BCN7482
CAS No.:7222-35-7
- Parsonsine
Catalog No.:BCN2111
CAS No.:72213-98-0
- Calcitetrol
Catalog No.:BCC1446
CAS No.:72203-93-1
- Aflatoxin B2
Catalog No.:BCC9213
CAS No.:7220-81-7
- 2-Hydroxyplatyphyllide
Catalog No.:BCN7119
CAS No.:72145-19-8
- b-Casomorphin (1-3)
Catalog No.:BCC1007
CAS No.:72122-59-9
- Nerolidol
Catalog No.:BCN5459
CAS No.:7212-44-4
- Prilocaine
Catalog No.:BCC4929
CAS No.:721-50-6
- Mastoparan X
Catalog No.:BCC5833
CAS No.:72093-22-2
- 5(6)-Carboxyfluorescein
Catalog No.:BCC8283
CAS No.:72088-94-9
- Org 24598 lithium salt
Catalog No.:BCC7845
CAS No.:722456-08-8
- AZD1152
Catalog No.:BCC1393
CAS No.:722543-31-9
- Barasertib (AZD1152-HQPA)
Catalog No.:BCC2168
CAS No.:722544-51-6
- Malvidin-3-O-glucoside chloride
Catalog No.:BCN3031
CAS No.:7228-78-6
- Streptolydigin
Catalog No.:BCN1858
CAS No.:7229-50-7
- Sulfamethoxazole
Catalog No.:BCC4857
CAS No.:723-46-6
- 9-AC
Catalog No.:BCC6867
CAS No.:723-62-6
- Rivularine
Catalog No.:BCN2038
CAS No.:723-78-4
- ZLN024
Catalog No.:BCC5527
CAS No.:723249-01-2
- ZJ 43
Catalog No.:BCC2355
CAS No.:723331-20-2
- Beta-Carotene
Catalog No.:BCN4965
CAS No.:7235-40-7
- Licoflavone C
Catalog No.:BCN3256
CAS No.:72357-31-4
Screening and identification of Caulis Sinomenii bioactive ingredients with dual-target NF-kappaB inhibition and beta2- AR agonizing activities.[Pubmed:27187693]
Biomed Chromatogr. 2016 Nov;30(11):1843-1853.
Caulis Sinomenii (CS) is a valuable traditional medicine in China. Its extract can act as an anti-inflammatory agent and a vascular smooth muscle relaxant. However, the underlying mechanisms remain unknown. In this study, we developed a simple dual-target method based on ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry combined with a dual-target bioactive screening assay for anti-inflammatory and antispasmodic activities to characterize the chemical structure of various bioactive compounds of CS rapidly. Seven potential NF-kappaB inhibitors were identified, including laudanosoline-1-O-xylopyranose, 6-O-methyl-laudanosoline-1-O-glucopyranoside, menisperine, sinomenine, Laurifoline, magnoflorine and norsinoacutin. Furthermore, IL-6 and IL-8 assays confirmed the anti-inflammatory effects of these potential NF-kappaB inhibitors, in which laudanosoline-1-O-d-xylopyranose and menisperine were revealed as novel NF-kappaB inhibitors. Among the seven identified alkaloids, three potential beta2 -adrenergic receptor agonists, including sinomenine, magnoflorine and Laurifoline, were characterized using a luciferase reporter system to measure for the activity of beta2 -adrenergic receptor agonists. Finally, sinomenine, magnoflorine and Laurifoline were identified not only as potential NF-kappaB inhibitors but also as potential beta2 -adrenegic receptor agonists, which is the first time this has been reported. Molecular dynamic simulation and docking results suggest that the three dual-bioactive constituents could not only inhibit Pseudomonas aeruginosa PAK strain-induced inflammatory responses via a negative regulation of the Braf protein that participates in MAPK signaling pathway but also activate the beta2 -adrenegic receptor. These results suggest that CS extract has dual signaling activities with potential clinical application as a novel drug for asthma.
Two new alkaloids and active anti-hepatitis B virus constituents from Hypserpa nitida.[Pubmed:17723297]
Bioorg Med Chem Lett. 2007 Oct 1;17(19):5316-20.
Two new alkaloids, hypserpanines A and B (1, 11), together with eleven known compounds, phenolbetain (2), acutumine (3), acutumidine (4), dechloroacutumine (5), dauricumine (6), dauricumidine (7), pronuciferine (8), glaziovine (9), S-reticuline (10), magnoflorine (12) and Laurifoline(13), were isolated from Hypserpa nitida Miers. (Menispermaceae) and chemically elucidated through spectral analyses. All the isolated alkaloids were evaluated for their anti-HBV activities in vitro using the HBV transfected Hep G2.2.15 cell line. The most active compound, dauricumidine (7), exhibited an IC(50) value of 0.450 mM (SI=4.13) on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the Hep G2.2.15 cell line.
